These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23106934)

  • 21. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
    Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
    Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parathyroid subcutaneous pre-sternal transplantation after parathyroidectomy for renal hyperparathyroidism. Long-term graft function.
    Echenique-Elizondo M; Amondarain JA; Vidaur F; Olalla C; Aribe F; Garrido A; Molina J; Rodrigo MT
    World J Surg; 2007 Jul; 31(7):1403-9. PubMed ID: 17516108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.
    Kovacevic B; Ignjatovic M; Zivaljevic V; Cuk V; Scepanovic M; Petrovic Z; Paunovic I
    Langenbecks Arch Surg; 2012 Mar; 397(3):413-20. PubMed ID: 22240976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Status of Serum Calcium, Phosphate and Intact Parathyroid Hormone in Predialysis Chronic Kidney Disease Patients of Stage-3 to Stage-5 Compared To KDOQI Guideline.
    Hai AA; Rahman MM; Anwar MR; Miah OF; Latif A; Jalil ME; Razzak MA; Morshed AM; Mahmud H; Dowel FA
    Mymensingh Med J; 2021 Oct; 30(4):1031-1042. PubMed ID: 34605474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
    Yusuf AA; Howell BL; Powers CA; St Peter WL
    Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Moldovan D; Racasan S; Kacso IM; Rusu C; Potra A; Bondor C; Patiu IM; Gherman-Căprioară M
    Int Urol Nephrol; 2015 Nov; 47(11):1871-7. PubMed ID: 26377492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
    Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
    Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
    Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
    Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.
    Chen H; Cui Y; Xing C; Purrunsing Y; Zha X; Shen C; Zeng M; Yang G; Yu X; Zhang L; Jiang Y; Shen Z; Ma H; Yin C; Li Y; Wang N
    Int Urol Nephrol; 2018 Dec; 50(12):2279-2288. PubMed ID: 30361964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment].
    Eremkina AK; Elfimova AR; Aboisheva EA; Karaseva EV; Fadeeva MI; Maganeva IS; Kovaleva EV; Gorbacheva AM; Bibik EE; Mokrysheva NG
    Probl Endokrinol (Mosk); 2022 Aug; 68(4):52-58. PubMed ID: 36104966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes following parathyroidectomy for secondary hyperparathyroidism in patients with chronic kidney disease: a single-centre study.
    Bali P; Toussaint ND; Tiong MK; Ruderman I
    Intern Med J; 2022 Dec; 52(12):2107-2115. PubMed ID: 34339094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study.
    Molina P; Molina MD; Pallardó LM; Torralba J; Escudero V; Álvarez L; Peris A; Sánchez-Pérez P; González-Rico M; Puchades MJ; Fernández-Nájera JE; Giménez-Civera E; D'Marco L; Carrero JJ; Górriz JL
    J Nephrol; 2021 Aug; 34(4):1189-1199. PubMed ID: 33394344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Different Levels of iPTH on All-Cause Mortality in Dialysis Patients with Secondary Hyperparathyroidism after Parathyroidectomy.
    Xi QP; Xie XS; Zhang L; Zhang R; Xiao YF; Jin CG; Li YB; Wang L; Zhang XX; Du ST
    Biomed Res Int; 2017; 2017():6934706. PubMed ID: 28656147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.
    Ge Y; Yang G; Wang N; Zha X; Yu X; Mao H; Sun B; Zeng M; Zhang B; Xing C
    Int Urol Nephrol; 2019 Aug; 51(8):1443-1449. PubMed ID: 31264087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of and risk factors for post-parathyroidectomy hungry bone syndrome in patients with secondary hyperparathyroidism.
    Kritmetapak K; Kongpetch S; Chotmongkol W; Raruenrom Y; Sangkhamanon S; Pongchaiyakul C
    Ren Fail; 2020 Nov; 42(1):1118-1126. PubMed ID: 33143476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.
    Lee SA; Lee MJ; Ryu GW; Jhee JH; Kim HW; Park S; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Yoo TH
    Osteoporos Int; 2016 Sep; 27(9):2717-2726. PubMed ID: 27216997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroidectomy in patients with chronic kidney disease: Impacts of different techniques on the biochemical and clinical evolution of secondary hyperparathyroidism.
    Albuquerque RFC; Carbonara CEM; Martin RCT; Dos Reis LM; do Nascimento CP; Arap SS; Moysés RMA; Jorgetti V; Montenegro FLM; de Oliveira RB
    Surgery; 2018 Feb; 163(2):381-387. PubMed ID: 29146232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.
    Oltmann SC; Madkhali TM; Sippel RS; Chen H; Schneider DF
    J Surg Res; 2015 Nov; 199(1):115-20. PubMed ID: 25982045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Nomogram to Predict Hungry Bone Syndrome After Parathyroidectomy in Patients With Secondary Hyperparathyroidism.
    Wang M; Chen B; Zou X; Wei T; Gong R; Zhu J; Li Z
    J Surg Res; 2020 Nov; 255():33-41. PubMed ID: 32540578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.